• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ZenGUARD(TM) Enhanced Air Filters to Be Added as Class 1 Medical Device Under Zentek's Medical Device Establishment Licence

    11/27/24 8:45:00 AM ET
    $ZTEK
    Major Chemicals
    Industrials
    Get the next $ZTEK alert in real time by email

    GUELPH, ON / ACCESSWIRE / November 27, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, announces its decision that its ZenGUARD™ Enhanced Air Filters will be added under the company's existing medical device establishment licence ("MDEL"), similar to ZenGUARD™ Surgical Masks.

    • Initial test work and validation began on ZenGUARD™ Enhanced Air Filters in early 2021, culminating in the award of an Innovative Solutions Canada ("ISC") Testing Stream.

    • The purpose of the ISC Testing Stream - The Government of Canada contract awarded in 2021 - was to determine whether ZenGUARD™ Enhanced Air Filters could achieve a significant net reduction in airborne respiratory pathogens, thereby validating it as an effective device to mitigate the transmission of disease.

    • Independent proof-of-concept testing and validation was completed by the National Research Council of Canada in their unique bioaerosol facility, a purpose-built modular room intended to simulate the risk of infection in a real-world classroom environment. LMS Technologies Inc. was subsequently contracted to test ZenGUARD™ Enhanced Air Filter finished products and reported an average viral filtration efficiency ("VFE") enhancement of ~66% compared to an untreated filter, or an average ~67% VFE under simulated operating conditions over 6 months with negligible change in pressure drop.

    • This extensive testing program was conducted over the course of approximately two years and successfully demonstrated that ZenGUARD™ Enhanced Air Filters can achieve a significant reduction in airborne respiratory pathogens to help mitigate the transmission of disease indoors.

    • To further validate this, the Company completed a study with ParticleOne, a RWDI Ventures company. ParticleOne's computational model showcased ZenGUARD™ Enhanced Air Filter's viral filtration action, effectively reducing the spread of viral pathogens and enhancing indoor safety. It also demonstrated potential cost savings from absenteeism related to poor indoor air quality.

    Quality Management System

    Prior to distributing and selling an additional medical device in Canada, certain testing, process updates and additional documentation related to the Company's supply chain will be required to qualify ZenGUARD™ Enhanced Air Filters as a medical device under its MDEL and ensure compliance with its ISO 13485:2016 Quality Management System. While this process will take additional time and resources, the Company expects it to be significantly less than that required under the previous pathway to market being pursued.

    "ZenGUARD™ Enhanced Air Filters will offer a safe and effective way to help prevent the transmission of disease indoors without increasing energy consumption and emissions. This unique value proposition was borne out of an ask from the Government of Canada's Innovation Science and Economic Development agency - and we look forward to fulfilling that ask and helping many others in Canada with a safe and effective technology," said Greg Fenton, CEO of Zentek.

    Management Changes

    The Company also announces that Nick Hansford, Vice President, Strategy and Product Development, and member of the Zentek management team, has left the company to pursue other opportunities.

    About Zentek Ltd.

    Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

    Zentek's patented technology platform ZenGUARD™ is shown to have enhanced viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.

    For further information on Zentek:

    [email protected]

    Ryan Shacklock
    Senior VP, Strategy & Business Development
    Email: [email protected]
    Phone: 306-270-9610

    To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.

    Forward-Looking Statements

    This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE: Zentek



    View the original press release on accesswire.com

    Get the next $ZTEK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What recent decision did Zentek Ltd. announce regarding ZenGUARD™ Enhanced Air Filters?

      Zentek has decided to add its ZenGUARD™ Enhanced Air Filters under its existing medical device establishment licence (MDEL), similar to its ZenGUARD™ Surgical Masks.

    • What was the purpose of the Government of Canada contract awarded to Zentek in 2021?

      The ISC Testing Stream contract was awarded to determine if the ZenGUARD™ Enhanced Air Filters significantly reduce airborne respiratory pathogens to validate its effectiveness in mitigating disease transmission.

    • What were the results of the independent proof-of-concept testing for ZenGUARD™ Enhanced Air Filters?

      Independent testing by the National Research Council of Canada showed that ZenGUARD™ Enhanced Air Filters can achieve an average ~66% to ~67% viral filtration efficiency (VFE) enhancement compared to untreated filters over six months.

    • What steps does Zentek need to take to qualify ZenGUARD™ Enhanced Air Filters as a medical device?

      Zentek plans to undertake additional testing, process updates, and documentation to comply with ISO 13485:2016 Quality Management System before distributing the filters, which is expected to take less time than the previous market pathway.

    • What is the unique value proposition of ZenGUARD™ Enhanced Air Filters according to CEO Greg Fenton?

      Greg Fenton noted that ZenGUARD™ Enhanced Air Filters will provide a safe and effective method to prevent disease transmission indoors without increasing energy consumption, responding to a request from the Canadian government.

    Recent Analyst Ratings for
    $ZTEK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZTEK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zentek Provides Update on ZenGUARD(TM) Enhanced Air Filters for the Canadian Market

      GUELPH, ON / ACCESS Newswire / January 17, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide an update on the launch of ZenGUARD™ Enhanced Air Filters in the Canadian Market.The Company is prioritizing the completion of all required documentation to support the manufacture and sale of ZenGUARD™ Enhanced Air Filters under its existing medical device establishment licence ("MDEL") alongside ZenGUARD™ Surgical Masks. This documentation will be completed in compliance with Canadian Medical Device Regulations (MDR) and ISO 13485:2016 Quality Management System for medical devices.The Com

      1/17/25 8:00:00 AM ET
      $ZTEK
      Major Chemicals
      Industrials
    • Zentek Subsidiary Albany Graphite Corp. Simplifies Process to Achieve Five Nines Purity

      GUELPH, ON / ACCESSWIRE / January 8, 2025 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company is pleased to announce that its wholly owned subsidiary, Albany Graphite Corporation (AGC) has achieved a preliminary five-nines purity of 99.9991% directly from a larger Albany graphite deposit flotation concentrate sample utilizing an operational pilot-scale fluidized bed reactor (FBR).HighlightsUltra-high purity "five nines" 99.9991 wt.% from a platinum crucible Loss on Ignition (LOI) analysisPurification was performed utilizing an existing pilot-scale FBR directly on a ~950 g sample of the Albany flotati

      1/8/25 9:10:00 AM ET
      $ZTEK
      Major Chemicals
      Industrials
    • Zentek Provides Update on International Opportunities

      GUELPH, ON / ACCESSWIRE / December 12, 2024 / Zentek Ltd. (" Zentek "or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, has signed a Memorandum of Understanding ("MOU") with Al-Ramez International Group - through Saudi Excellence Holding Company - establishing a strategic partnership to drive innovation and commercialization in advanced technologies across the Kingdom of Saudi Arabia ("KSA") and the Middle East and North Africa ("MENA") region on November 14 th 2024.Memorandum of Understanding OverviewThe MOU outlines a collaborative framework where Zentek intends to contribute intellectual property, product licensing, and researc

      12/12/24 8:30:00 AM ET
      $ZTEK
      Major Chemicals
      Industrials

    $ZTEK
    SEC Filings

    See more
    • SEC Form 6-K filed by Zentek Ltd.

      6-K - Zentek Ltd. (0001904501) (Filer)

      5/16/25 9:50:10 AM ET
      $ZTEK
      Major Chemicals
      Industrials
    • SEC Form 6-K filed by Zentek Ltd.

      6-K - Zentek Ltd. (0001904501) (Filer)

      4/23/25 10:18:41 AM ET
      $ZTEK
      Major Chemicals
      Industrials
    • SEC Form 6-K filed by Zentek Ltd.

      6-K - Zentek Ltd. (0001904501) (Filer)

      4/17/25 4:35:03 PM ET
      $ZTEK
      Major Chemicals
      Industrials

    $ZTEK
    Leadership Updates

    Live Leadership Updates

    See more
    • Zentek Reports Improvements and Expansion of its Aptamer-Based Platform Technology

      GUELPH, ON / ACCESSWIRE / November 15, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company announces the development of a significant upgrade to its aptamer platform improving the binding affinity of the universal Covid-19 aptamer from 300 to over 500 times, compared to the base aptamer. The improved platform has also solved key challenges for manufacturing and these High-Binding Affinity (HBA) aptamers are now produced with approximately a 95% yield. A key roadblock of translating a promising lead candidate (lab-scale therapeutic) into a commercial product is cost-effective and high-purity manu

      11/15/23 8:15:00 AM ET
      $ZTEK
      Major Chemicals
      Industrials
    • Zentek Announces the Launch of Subsidiary for Aptamer-Based Platform Technology

      GUELPH, ON / ACCESSWIRE / October 5, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company announces the launch of a wholly-owned subsidiary that will own the exclusive, global licensing rights for all aptamer-based technology from the collaboration with McMaster University. This licensing agreement includes the rapid-detection platform and the recent aptamer-based platform technology developed by Dr. Yingfu Li and his team that is showing promise as a therapeutic through preclinical studies being conducted by Dr. Matthew Miller and his team. This new entity has been launched as a vehicle to accel

      10/5/23 7:15:00 AM ET
      $ZTEK
      Major Chemicals
      Industrials
    • Zentek Announces Appointment of New Director of Investor Relations

      GUELPH, ON / ACCESSWIRE / January 12, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK);(TSXV:ZEN), an intellectual property development and commercialization company, welcomes Mr. Mitch Swergold as its Director of Investor Relations.Mr. Swergold earned a Bachelor of Arts in Political Science from Columbia University in the City of New York, and a Juris Doctor degree from Emory University School of Law. After practicing law and serving as a research analyst at two investment banks, Mr. Swergold was a Senior Analyst and Portfolio Manager at various hedge funds, focusing on technology and macroeconomic investing."Mitch's experience investing in technology companies, from early to la

      1/12/23 8:00:00 AM ET
      $ZTEK
      Major Chemicals
      Industrials